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Supplementary Figure 1 – Development of a muscle-optimized AAV-based antibody expression 
vector 
 
a, (left) Quantitation of luciferase activity by Xenogen imaging of Rag2-/-"c-/- mice receiving 
intramuscular injection of 1x1010 or 1x1011 GC of AAV2/8 encoding luciferase demonstrates long-term 
dose-dependent expression (n=2). (right) Concentration of human IgG in circulation as measured by total 
human IgG ELISA on serum samples taken after intramuscular injection of 1x1010 or 1x1011 GC of 
AAV2/8 expressing 4E10-IgG1into Rag2-/-"c-/- mice  (n=2).  Antibody production is dose-dependent and 
is maintained for at least 64 weeks. b, Comparison of luciferase activity 15 weeks after intramuscular 
injection of 2x109 GC of AAV2/8 vectors expressing luciferase from a panel of promoters (n=2). c, 
Design of the CASI promoter combining the CMV enhancer and chicken !-actin promoter followed by a 
splice donor (SD) and splice acceptor (SA) flanking the ubiquitin enhancer region. d, Comparison of 
luciferase activity from vectors driven by CASI as compared to conventional promoters 8 weeks after 
intramuscular injection of 1x109 GC of AAV2/8 encoding luciferase driven by the indicated promoter 
(n=2). e, Comparison of luciferase activity 6 weeks post-administration of CMV-driven vectors with or 
without WPRE, terminated by the indicated polyadenylation signal (n=2). f, Schematic representation of 
the VIP expression vector for antibody expression indicating the inverted terminal repeats (ITR), the 
CASI promoter, an IgG1 heavy chain linked to kappa light chain separated by a self-processing 2A 
sequence, a WPRE for improved expression and SV40 late-polyadenylation signal. Antibody V-regions 
of heavy and light chains are cloned into the vector at positions indicated in red.  
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Supplementary Figure 2 – Map of the modular pVIP vector 
 
Schematic representation of the pVIP transfer vector with unique restriction sites flanking each modular 
element designated in red.  AAV sequences begin immediately following the XhoI restriction site with a 
145bp “flip”-ITR from AAV2 followed by a SpeI restriction site and the immediate early CMV promoter.  
The promoter is followed by a NotI restriction site and one additional C residue to mimic a Kozak 
consensus sequence prior to the ATG of the luciferase transgene.  The 3’ end of the transgene is 
terminated with a TAA stop codon followed by one additional A residue prior to the BamHI site.  The 
WPRE element follows this restriction site and continues until an Acc65I restriction site that precedes an 
SV40 polyadenylation signal and HindIII restriction site.  Finally, a second 145bp AAV2 “flop”-ITR is 
located prior to an NheI site. 
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Supplementary Figure 3 – Optimization of the IgG1 transgene in vitro 
 
a, Schematic representation of the IgG1 transgene that was optimized for expression in vitro.  
Highlighted are the heavy and light chain signal sequences (blue) the F2A self-processing peptide (green) 
and the predicted splice donor and acceptor sites (red lines). b, Comparison of antibody expression in 
vitro by ELISA following transfection with vectors carrying the antibody transgene shown above with 
standard or optimized F2A sequences that include a furin cleavage site. c, Comparison of 4E10 antibody 
expression in vitro by ELISA following transfection with vectors carrying 4E10 with natural or human 
growth hormone (HGH) derived signal peptides fused to the heavy chain gene, the light chain gene or 
both genes. d, Comparison of 4E10 antibody expression in vitro by ELISA following transfection with 
vectors carrying 4E10 in the standard expression cassette or a cassette in which the splice donors and 
acceptors were mutated to reduce the potential for extraneous splicing. 
d 
SUPPLEMENTARY INFORMATION
4  |  w w w. n a t u r e . c o m / n a t u r e
RESEARCH
Supplementary Figure 4 – Neutralization of HIV by Antibodies expressed from an optimized 
expression transgene 
 
To confirm that antibodies expressed from the optimized expression transgene retained their function, an 
in vitro protection assay using TZM-bl luciferase reporter cells was conducted.  Cells were plated with 
the indicated concentrations of b12 (a), 2G12 (b), 4E10 (c) or 2F5 (d) prior to challenge with increasing 
titers of NL4-3.  Two days after challenge, cells were lysed and quantitated for luciferase activity 
following the addition of luciferin substrate. (n=3, RLU=Relative luciferase Units).  
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Supplementary Figure 5 – Depletion of CD4 cells in vivo following HIV challenge of humanized 
mice 
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FG'@(#F+(7H+.I(C'J+EK(To confirm that antibodies expressed from the optimized expression transgene 
retained their function, an in vitro protection assay using TZM-bl luciferase reporter cells was conducted.  
Cells were plated with the indicated concentrations of b12 (a), 2G12 (b), 4E10 (c) or 2F5 (d) prior to 
challenge with increasing titers of NL4-3.  Two days after challenge, cells were lysed and quantitated for 
luciferase activity following the addition of luciferin substrate. (n=3, RLU=Relative luciferase Units).  
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Supplementary Figure 6 – Serum concentrations of total human IgG and gp120 binding IgG prior 
to HIV challenge 
 
a, Concentration of total human antibody produced by engrafted cells and VIP as measured by human 
IgG ELISA on serum samples taken 5 weeks after intramuscular injection of vectors expressing either 
luciferase or b12 antibody and 3 weeks after adoptive transfer of human PBMCs and the day prior to IV 
HIV challenge (n=8). b, Concentration of antibody at the same time point quantified using a gp120-
specific ELISA to measure the concentration of antibody specific for HIV (n=8). 
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Supplementary Figure 7 – Determination of the minimum protective dose of b12  in vivo(
a, b12 expression over time as a function of dose as determined by total human IgG ELISA on serum 
samples taken following AAV administration (n=8). Mice receiving luciferase-expressing vector 
exhibited no detectable human antibodies (n=12). b, Concentration of b12 in serum one day prior to 
challenge, 3 weeks after adoptive transfer of human PBMCs and 15 weeks after intramuscular 
administration of the indicated dose of AAV as determined by a gp120-specific ELISA to measure the 
fraction of antibodies capable of binding HIV (n=8-12).  c, CD4 cell depletion in HuPBMC-NSG 
humanized mice as a result of intravenous challenge with 10ng of NL4-3 into animals expressing a range 
of b12 demonstrating the minimum dose of antibody necessary to protect against infection.  Plots a and c 
show mean and standard error, plot b shows individual animals and mean (n=8-12).(
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Supplementary Results 
Optimal vectors for muscle-based antibody expression 
To rapidly test novel vector configurations, we created a modular AAV transfer vector 
that implemented unique restriction sites flanking each modular element (Supplementary Fig. 2).  
To identify active promoters ideally suited to muscle expression, we created a series of vectors 
carrying the luciferase gene driven by a panel of ubiquitous and tissue-specific promoters.  These 
vectors were administered intramuscularly via a single injection in the gastrocnemius muscle and 
luciferase expression was monitored to determine the relative expression potential of each 
promoter in this target tissue (Supplementary Fig. 1b).  We identified the cytomegalovirus 
immediate early promoter (CMV), chimeric chicken-!-actin (CAG), and ubiquitin C (UBC) 
promoters as optimal for long-term muscle expression.  Based on these findings, we created a 
novel promoter that combined these three promoters along with consensus splice donor and 
acceptor sequences to produce the CASI promoter design (Supplementary Fig. 1c).  Further in 
vivo testing demonstrated that the CASI promoter was considerably more active in muscle than 
the CAG promoter despite being 34% more compact (Supplementary Fig. 1d).  This reduced size 
allowed us to incorporate the woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE)39, which we confirmed to significantly enhance expression of transgenes 
(Supplementary Fig. 1e).   To determine the relative efficiency of polyadenylation signals for 
muscle-derived expression, we tested the SV40 late poly(A), the rabbit beta-globin (RBG) 
poly(A) and the bovine growth hormone (BGH) poly(A), all of which demonstrated comparable 
levels of expression (Supplementary Fig. 1e).  Based on these results, we designed a muscle-
optimized expression vector encoding an IgG1 scaffold into which heavy and light chain V-
regions derived from monoclonal antibodies could be inserted (Supplementary Fig. 1f).  
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Optimization of the antibody transgene 
To create an optimal framework for the expression of antibody, we cloned the heavy and 
light chains of several broadly neutralizing HIV antibodies separated by an F2A self-processing 
peptide sequence40 (Supplementary Fig. 3a) into a mammalian expression vector under the 
control of the CMV promoter.  293T cells transfected with these vectors demonstrated secretion 
of human IgG into the culture supernatant that could be detected by ELISA (Supplementary Fig. 
3b).  In an attempt to improve expression, we re-engineered the F2A sequence to better reflect 
mammalian codon usage and incorporated a furin cleavage site at the N-terminus for optimal 
processing22.  Comparison of these F2A optimized vectors by transfection showed they produced 
higher levels of all four antibodies tested.  
We next sought to improve secretion of antibody by replacing the endogenous signal 
sequences with a codon optimized sequence derived from the well-characterized human growth 
hormone (HGH) and created versions of the 4E10 expression vector in which either the heavy 
chain, the light chain, or both chains were driven by separate HGH signal sequences and 
compared their expression by transfection.  To minimize repetitive sequence in our viral vectors, 
two HGH sequences were synthesized which had distinct nucleotide sequences but encoded 
identical amino acids, and each were used for either the heavy or light chain exclusively.   
Replacement of the endogenous signal sequences with HGH sequences at either the heavy or 
light chains resulted in higher levels of antibody production, and signal sequence replacement of 
both chains yielded the best results (Supplementary Fig. 3c). 
To remove the potential for inappropriate splicing of the transcript encoding the antibody, 
we subjected the sequence to in silico splice prediction41 and removed all potential splice donor 
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and acceptor sequences through the use of conservative mutations to the site or, when this was 
not possible, the surrounding sequences.  We observed improved expression of the 4E10 
antibody when placed in this splice-optimized framework (Supplementary Fig. 3d).  The final 
antibody transgene consists of an HGH signal sequence followed by a swappable VH region, a 
splice-optimized heavy chain constant region, a furin cleavage site linked to an optimized F2A 
peptide which is fused to a second HGH signal sequence, a swappable VL region, and a splice-
optimized kappa light chain constant region. 
Validation of transgene-expressed antibody activity  
To confirm that the optimizations made to improve gene expression did not impact the 
neutralizing efficacy of the antibodies, we expressed several well-studied broadly neutralizing 
antibodies from this expression cassette and tested these purified proteins in an in vitro 
protection assay. Cells carrying a luciferase gene under the control of HIV-induced 
transcriptional elements (TZM-bl cells) were incubated with dilutions of each antibody prior to 
challenge with increasing amounts of HIV.  We observed robust reduction in TZM-bl cell 
infection at antibody concentrations that correlated well with the previously established IC50 and 
IC90 values for all antibodies tested against this strain (Supplementary Fig. 4). 
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